汉邦科技：精粹色谱科技致力人类健康 打造国际色谱行业第一品牌——江苏汉邦科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放

Core Viewpoint - The company, Jiangsu Hanbang Technology Co., Ltd., focuses on chromatography technology, aiming to become the leading brand in the international chromatography industry while providing high-quality separation and purification equipment for the pharmaceutical and life sciences sectors [4][5][7]. Business Overview - The company specializes in chromatography separation and purification products, offering a comprehensive product matrix that includes small and large molecule drug separation and purification equipment [5]. - The main product lines include small molecule liquid chromatography systems and large molecule chromatography systems, catering to both laboratory research and industrial production [5]. R&D Model - The company adopts an independent R&D model with dedicated departments for instrument development, application technology, and new materials [6]. - R&D strategies are guided by customer needs and industry trends, leading to the development of new products and continuous improvement of existing ones [6]. Core Technology - The company has developed unique core technologies in chromatography, including preparation chromatography column technology and integrated chromatography system technology [7]. - It has undertaken multiple national and provincial research projects, enhancing its technological capabilities [7]. Financial Performance - The company's revenue for 2022, 2023, and 2024 was approximately 481.79 million, 619.01 million, and 690.88 million yuan, respectively, with over 99% of revenue coming from its main business [11]. - Gross profit for the same years was approximately 189.24 million, 245.08 million, and 293.57 million yuan, showing a consistent growth trend [11]. Product Profitability - The gross profit margin for small molecule drug separation and purification equipment was 43.87%, 42.13%, and 46.90% from 2022 to 2024, while for large molecule equipment, it was 31.79%, 34.72%, and 31.55% [12]. Future Development Plans - The company plans to continue focusing on chromatography products, enhancing R&D and innovation, and expanding its product range in the biopharmaceutical chromatography purification field [13]. - Specific measures include strengthening talent development, enhancing marketing and service capabilities, and diversifying financing [13]. Competitive Advantages - The company possesses several competitive advantages, including technological innovation, comprehensive solution services, brand leadership, rapid response, and strong customer resources [14][19]. Industry Trends - The pharmaceutical equipment industry is experiencing rapid growth driven by the Chinese pharmaceutical market, with increasing demand for both small and large molecule chromatography systems [20][21]. - The industry is also seeing a shift towards high-end products and smart manufacturing, supported by national policies [21]. Market Position - The company ranks second in the production-level small molecule liquid chromatography equipment market in China, with a market share of approximately 12.7% [22]. - In the production-level small molecule liquid chromatography system market, the company holds a leading position with a market share of 39.2% [22]. Fundraising Projects - The company plans to invest in projects including the annual production of 1,000 liquid chromatography series separation equipment and the establishment of a chromatography separation equipment R&D center [24][25][26].